Molecular basis of BET family protein inhibition by four clinical-stage small-molecule inhibitor drugs
Lin, S.; You, Y.; Chen, X.; Lu, G.
Show abstract
The bromodomain and extra-terminal (BET) family proteins are critical epigenetic readers involved in various diseases, making them attractive therapeutic targets. This study elucidates the molecular basis of inhibition by four clinical-stage BET inhibitors (ZEN-3694, INCB054329, PLX51107, and INCB057643) through detailed structural comparison and analysis. Using X-ray crystallography, we determined their complex structures with the second bromodomain of human BRD2 at 1.4-1.5 [A] resolution. All inhibitors occupy the conserved acetyl-lysine binding pocket via extensive hydrophobic interactions. This hydrophobic network is further coupled with hydrogen-bond contacts for inhibitor-binding stabilization. A common feature is the formation of at least one hydrogen bond with a conserved residue of N429. Notably, INCB057643 exhibits an enhanced polar network, forming additional hydrogen bonds with residues D377 and N429, which may contribute to its improved pharmacological profile. These structures reveal a shared competitive inhibition mechanism by occluding the acetyl-lysine binding site, providing a rational basis for their transcriptional repression and guiding future inhibitor design.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 Macrodomain of SARS-CoV-2 95%
- An influenza A hemagglutinin small-molecule fusion inhibitor identified by a new high-throughput fluorescence polarization screen. 94%
- Structural convergence for tubulin binding of CPAP and vinca domain microtubule inhibitors 94%
Similar papers in this journal
Similar papers in this journal
- Impact of combinatorial histone modifications on acetyllysine recognition by the ATAD2 and ATAD2B bromodomains 93%
- DFG-1 residue controls inhibitor binding mode and affinity providing a basis for rational design of kinase inhibitor selectivity 93%
- FDA drug repurposing uncovers modulators of dopamine D2 receptor localization via disruption of the NCS-1 interaction 93%
Similar papers in this journal
- Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking 95%
- Structural insights into TRAP association with ribosome-Sec61 complex, and translocon inhibition by a CADA derivative 94%
- The mechanisms of catalysis and ligand binding for the SARS-CoV-2 NSP3 macrodomain from neutron and X-ray diffraction at room temperature 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.